Patents by Inventor Barton Haynes
Barton Haynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10626168Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.Type: GrantFiled: March 29, 2018Date of Patent: April 21, 2020Assignees: REGENERON PHARMACEUTICALS, INC., DUKE UNIVERSITYInventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
-
Publication number: 20180298082Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.Type: ApplicationFiled: March 29, 2018Publication date: October 18, 2018Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
-
Patent number: 9963501Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.Type: GrantFiled: February 6, 2014Date of Patent: May 8, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Barton Haynes, Garnett Kelsoe, Israel Lowy, Aris I. Baras, Lynn MacDonald, John McWhirter, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy, George D. Yancopoulos
-
Patent number: 9855329Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.Type: GrantFiled: September 30, 2014Date of Patent: January 2, 2018Assignees: Los Alamos National Security, LLC, Dana-Farber Cancer Institute, Duke UniversityInventors: Bette T. M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
-
Publication number: 20160235836Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.Type: ApplicationFiled: September 30, 2014Publication date: August 18, 2016Applicants: Los Alamos National Security, LC/TAS, Duke University, Dana-Farber Cancer InstituteInventors: Bette T.M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
-
Publication number: 20140221625Abstract: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Inventors: BARTON HAYNES, GARNETT KELSOE, ISRAEL LOWY, ARIS I. BARAS, LYNN MACDONALD, JOHN MCWHIRTER, CAGAN GURER, KAROLINA A. MEAGHER, ANDREW J. MURPHY, GEORGE D. YANCOPOULOS
-
Publication number: 20080181906Abstract: The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for use in such a method.Type: ApplicationFiled: May 19, 2004Publication date: July 31, 2008Inventors: Barton Haynes, Leonard Spicer
-
Publication number: 20080085261Abstract: The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising suppressing the number and/or function of regulatory T cells. The invention further relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: October 19, 2005Publication date: April 10, 2008Inventors: Barton Haynes, Gregory Sempowski, James Peacock
-
Publication number: 20080057075Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: June 22, 2007Publication date: March 6, 2008Inventor: Barton Haynes
-
Publication number: 20080038284Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.Type: ApplicationFiled: November 7, 2005Publication date: February 14, 2008Inventors: Barton Haynes, Hua-Xin Liao
-
Publication number: 20080031890Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: April 13, 2007Publication date: February 7, 2008Applicant: DUKE UNIVERSITYInventors: Barton Haynes, S. Alam, Hua-Xin Liao
-
Publication number: 20070178562Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.Type: ApplicationFiled: September 17, 2004Publication date: August 2, 2007Inventors: Barton Haynes, Feng Gao, Bette Korber, Beatrice Hahn, George Shaw, Denise Kothe, Ying Ying Li, Julie Decker, Hua-Xin Liao
-
Publication number: 20070092936Abstract: The present invention relates, in general, to severe acute respiratory syndrome and, in particular, to a method of generating neutralizing antibodies to the virus. The invention further relates to methods of detecting the presence of the virus and to methods of treating infected individuals.Type: ApplicationFiled: May 10, 2004Publication date: April 26, 2007Inventors: Barton Haynes, Hua-Xin Liao
-
Publication number: 20070086946Abstract: The present invention relates, in general, to a method of assaying an immune response induced by an immunogen, and, more particularly, to a method of assaying a immunogen for its ability to induce a desired immune response, wherein the assay is effected in an autoimmune animal.Type: ApplicationFiled: September 7, 2006Publication date: April 19, 2007Applicant: DUKE UNIVERSITYInventor: Barton Haynes
-
Publication number: 20060204986Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: February 14, 2006Publication date: September 14, 2006Applicant: DUKE UNIVERSITYInventors: Barton Haynes, Dhavalkumar Patel, Munir Alam, Hua-Xin Liao
-
Publication number: 20060165687Abstract: The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising suppressing the number and/or function of regulatory T cells. The invention further relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: December 14, 2005Publication date: July 27, 2006Applicant: DUKE UNIVERSITYInventors: Barton Haynes, Gregory Sempowski, James Peacock
-
Publication number: 20060014148Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: July 23, 2003Publication date: January 19, 2006Inventors: Barton Haynes, David Montefiori
-
Publication number: 20060008467Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.Type: ApplicationFiled: October 27, 2004Publication date: January 12, 2006Applicants: DUKE UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Barton Haynes, Hua-Xin Liao, Norman Letvin
-
Publication number: 20050112136Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.Type: ApplicationFiled: October 27, 2004Publication date: May 26, 2005Applicants: DUKE UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Barton Haynes, Hua-Xin Liao, Norman Letvin